Three new cancer drugs could help AstraZenecaAZN make a dent in its lofty ambition to become an $80 billion company by 2030, an executive told Investor's Business Daily. On Sunday and Monday, ...

AstraZeneca is inching closer to its goal of reporting $80 billion in revenue by 2030 as the U.K. drugmaker pushes further into the U.S. and develops new oncology, rare disease and weight-loss drugs.

AstraZeneca has a tiered partnership model to meet sites where they are. Sites can move between the levels as their capacity and engagement evolves over time, but all levels provide the site with a ...

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting renal, cardiovascular and metabolic conditions such as chronic kidney disease (CKD), using the latter’s AI-driven ...